David J Straus (David Straus)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 9

Top Topics

Multiple Myeloma

Hodgkin Lymphoma

Diffuse Large B Cell Lymphoma

Top Venues

Leukemia & lymphoma

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Kurt S Bantilan, Alexandra N Smith, Matthew John Maurer, Julie Teruya-Feldstein, Matthew J Matasar, Alison J Moskowitz, David J Straus, Ariela Noy, Maria Lia Palomba, Steven M Horwitz, Paul A Hamlin, Carol S Portlock, James R Cerhan, Thomas M Habermann, Gilles Andre Salles, Grzegorz S Nowakowski, Craig H Moskowitz, Andrew D Zelenetz
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP. Blood advances 8 (9) (2024)
Kurt S Bantilan, Alexandra N Smith, Matthew John Maurer, Julie Teruya-Feldstein, Matthew J Matasar, Alison J Moskowitz, David J Straus, Ariela Noy, Maria Lia Palomba, Steven M Horwitz, Paul A Hamlin, Carol S Portlock, James R Cerhan, Thomas M Habermann, Gilles Andre Salles, Grzegorz S Nowakowski, Craig H Moskowitz, Andrew D Zelenetz
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP. Blood advances 8 (9) (2024)
Kurt S Bantilan, Alexandra N Smith, Matthew John Maurer, Julie Teruya-Feldstein, Matthew J Matasar, Alison J Moskowitz, David J Straus, Ariela Noy, Maria Lia Palomba, Steven M Horwitz, Paul A Hamlin, Carol S Portlock, James R Cerhan, Thomas M Habermann, Gilles Andre Salles, Grzegorz S Nowakowski, Craig H Moskowitz, Andrew D Zelenetz
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP. Blood advances 8 (9) (2024)
Kurt S Bantilan, Alexandra N Smith, Matthew John Maurer, Julie Teruya-Feldstein, Matthew J Matasar, Alison J Moskowitz, David J Straus, Ariela Noy, Maria Lia Palomba, Steven M Horwitz, Paul A Hamlin, Carol S Portlock, James R Cerhan, Thomas M Habermann, Gilles Andre Salles, Grzegorz S Nowakowski, Craig H Moskowitz, Andrew D Zelenetz
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP. Blood advances 8 (9) (2024)
David A Qualls, Ariela Noy, David J Straus, Matthew J Matasar, Craig H Moskowitz, Venkatraman Seshan, Ahmet Dogan, Gilles Andre Salles, Anas Younes, Andrew D Zelenetz, Connie Lee Batlevi
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study. Leukemia & lymphoma 64 (3) (2023)
David A Qualls, Ariela Noy, David J Straus, Matthew J Matasar, Craig H Moskowitz, Venkatraman Seshan, Ahmet Dogan, Gilles Andre Salles, Anas Younes, Andrew D Zelenetz, Connie Lee Batlevi
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study. Leukemia & lymphoma (2023)
David A Qualls, Ariela Noy, David J Straus, Matthew J Matasar, Craig H Moskowitz, Venkatraman Seshan, Ahmet Dogan, Gilles Andre Salles, Anas Younes, Andrew D Zelenetz, Connie Lee Batlevi
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study. Leukemia & lymphoma 64 (3) (2023)
David A Qualls, Ariela Noy, David J Straus, Matthew J Matasar, Craig H Moskowitz, Venkatraman Seshan, Ahmet Dogan, Gilles Andre Salles, Anas Younes, Andrew D Zelenetz, Connie Lee Batlevi
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study. Leukemia & lymphoma 64 (3) (2023)
Lindsey Elizabeth Roeker, Tatyana A Feldman, Jacob D Soumerai, Victoria Falco, Gail Panton, Colleen Dorsey, Andrew D Zelenetz, Lorenzo Falchi, Jae H Park, David J Straus, Camila Pena Velasquez, Sonia Lebowitz, Yehudit Fox, Kristen Battiato, Carissa Laudati, Meghan C Thompson, Elizabeth McCarthy, Sabrina Kdiry, Rosalba Martignetti, Teja Turpuseema, Michelle Purdom, Dana Paskalis, Hari P Miskin, Peter Sportelli, Lori A Leslie, Anthony R Mato
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (18) (2022)